Source: citybiz

PreciseDx: PreciseDx Uses AI to Predict Recurrence of Breast Cancer

New York-based PreciseDx, which recently closed a $20.7 million Series B, is poised to advance AI-based technology that can predict the risk of recurrence in breast cancer patients.

Read full article »

PreciseDx's Competitors | PreciseDx's News | PreciseDx's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

President & CEO

Wayne Brinster

CEO Approval Rating

90/100

PreciseDx is a New York-based AI platform that provides solutions such as cancer risk stratification and personalized treatment analytics for the healthcare industry.